Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

BACKGROUND: Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Syst Rev
Main Authors: Wilson, Florence R., Coombes, Megan E., Brezden-Masley, Christine, Yurchenko, Mariya, Wylie, Quinlan, Douma, Reuben, Varu, Abhishek, Hutton, Brian, Skidmore, Becky, Cameron, Chris
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237027/
https://ncbi.nlm.nih.gov/pubmed/30428932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13643-018-0854-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados